Digital Pathology Market Report 2026

Digital Pathology Market Overview

• Digital Pathology market size has reached to $1.42 billion in 2025 • Expected to grow to $3.29 billion in 2030 at a compound annual growth rate (CAGR) of 18.3% • Growth Driver: Digital Pathology Market Surges As Prevalence Of Cancer Drives Demand For Advanced Diagnostics • Market Trend: AI-Driven Global Lab Network Transforms Collaboration And Precision Pathology Innovation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Digital Pathology Market?

Digital pathology is the process of the use of digital imaging for pathology procedures. Digital pathology equipment converts glass slides into high-resolution digital images by utilizing slide scanner hardware, software, and services. These images can be viewed, managed, and analyzed on a computer or mobile screen. The main types of products in digital pathology include scanners, software, communication systems, and storage systems. The scanner uses microscopic array technology to produce a three-dimensional digital representation of a pathology slide for viewing and automated image analysis. The software transfers the data into a digital medium for image review and analysis and tissue image analysis. Communication systems are used to communicate between separate whole slide acquisition, storage, and viewing components and also to remote colleagues using real-time telepathology. Storage systems consist of the digital archives of samples which allows for long-term analysis and other predictive analytics. The different types of pathology are human pathology and veterinary pathology. It is used by pharmaceutical and biotechnology companies, hospitals and reference laboratories, and academic and research institutes for drug discovery, disease diagnosis, teleconsultation, and training and education.

What Is The Digital Pathology Market Growth Forecast?

The digital pathology market size is expected to see rapid growth in the next few years. It will grow to $3.29 billion in 2030 at a compound annual growth rate (CAGR) of 18.3%. The growth in the forecast period can be attributed to increasing investments in computational pathology, rising demand for precision diagnostics, expansion of digital pathology in drug discovery, growing integration of AI in disease diagnosis, increasing focus on interoperability and data sharing. Major trends in the forecast period include increasing adoption of whole slide imaging systems, rising use of ai-based image analysis software, growing expansion of remote pathology services, integration of cloud-based pathology platforms, enhanced focus on workflow automation.

Global Digital Pathology Market Segmentation

1) By Product: Scanners, Software, Storage And Communication Systems 2) By Pathology Discipline: Human Pathology, Veterinary Pathology 3) By Application: Drug Discovery, Disease Diagnosis, Teleconsultation, Training And Education 4) By End-User: Pharmaceutical And Biotechnology Companies, Hospitals And Reference Laboratories, Academic And Research Institutes Subsegments: 1) By Scanners: Whole Slide Scanners, Tissue Microarray Scanners, Digital Imaging Systems 2) By Software: Image Analysis Software, Workflow Management Software, Diagnostic Software 3) By Storage And Communication Systems: Data Storage Solutions, Cloud-Based Platforms, Network And Communication Systems

What Is The Driver Of The Digital Pathology Market?

The increasing prevalence of cancer is driving the growth of the digital pathology market. As populations age, the risk of developing cancer increases due to cellular changes and prolonged exposure to risk factors. Moreover, factors such as smoking, poor diet, lack of physical activity, and excessive alcohol consumption contribute significantly to cancer risk. Digital pathology allows patients to accelerate the diagnosis and treatment of cancer, and thus an increase in cancer cases is driving the growth of the market. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. therefore, the increasing prevalence of cancer will propel digital pathology industry going forward.

Key Players In The Global Digital Pathology Market

Major companies operating in the digital pathology market are Danaher Corporation, Hoffmann-La Roche Ltd, Koninklijke Philips N.V, Hamamatsu Photonics K.K, 3DHISTECH Ltd, Olympus Corporation, Nikon Corporation, Leica Biosystems, Ventana Medical Systems, Sectra AB, Visiopharm A/S, Indica Labs Inc, PathAI, Paige.ai, Ibex Medical Analytics, Aiforia Technologies, Proscia, Inspirata Inc, Huron Digital Pathology, Akoya Biosciences, Aperio Digital Pathology, PerkinElmer, Definiens AG, Digipath, Apollo Enterprise Imaging Corp

Global Digital Pathology Market Trends and Insights

Major companies operating in the digital pathology market are focusing on developing advanced solutions such as collaborative AI-powered lab networks to enhance data sharing and clinical innovation. Collaborative AI-powered lab networks are interconnected pathology laboratories that use shared AI systems and data platforms to drive standardization, rapid turnaround, and real-world evidence generation. For instance, in July 2025, PathAI, a US-based provider of digital pathology and AI solutions, launched its Precision Pathology Network powered by its AISight image management system. The network connects anatomic pathology labs to biopharmaceutical partners and enables early access to AI algorithms while providing secure frameworks to share de-identified pathology data for translational research. Participating laboratories gain access to PathAI’s advanced algorithms, such as MET-Predict, and can monetize real-world pathology data, while biopharma companies benefit from a steady stream of clinical and molecular information for biomarker studies and precision drug development.

What Are Latest Mergers And Acquisitions In The Digital Pathology Market?

In August 2025, Tempus AI, Inc., a US-based provider of AI-enabled precision medicine and data-driven diagnostics, acquired Paige, a digital pathology company, for $81.25 million. With this acquisition, Tempus aims to expand its pathology dataset, strengthen its AI research capabilities, and build a leading footprint in digital pathology to accelerate its oncology AI model development. Paige, a US-based firm, develops AI applications for pathology and maintains a rich dataset of nearly 7 million clinically annotated digitized pathology slides.

Regional Outlook

North America was the largest region in the digital pathology market in 2025. Asia-Pacific was the second-largest region in the digital pathology market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Digital Pathology Market?

The digital pathology market consists of the sales of slide scanners, software, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.